English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

This editorial refers to ‘Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial’[†][1], by E.S. Chung et al. , on page 2228. Chronic heart failure (CHF), mainly caused by ischemic heart disease (IHD), represents the leading cause of disability and death in developed countries. The current standard of care does not provide a definitive solution for this condition, except for cardiac transplantation, which is hampered by the scarcity of organs and by rejection.1 Thus there is a compelling need for innovation in this field, in which regenerative medicine has emerged as the most promising hope for millions of patients worldwide.In this issue of the European Heart Journal , Chung and collegues2 report the results of a double-blind phase II clinical trial to assess the safety and efficacy of plasmid stromal cell-derived factor-1 (pSDF-1) in patients with CHF. Ninety-three patients with end-stage IHD were randomized 1:1:1 to receive transendocardial injections of 15 mg or 30 mg of pSDF-1 or placebo. The primary endpoint was a composite of 6-min walk distance and quality of life [Minnesota Living with Heart Failure Questionnaire (MLWHFQ)] at 4 … [1]: #fn-2

It is never too late for native cardiac repair: can genes awake the Sleeping Beauty in chronic patients?: Figure 1